Hemifacial myohyperplasia is due to somatic muscular PIK3CA gain-of-function mutations and responds to pharmacological inhibition
© 2023 Bayard et al..
Hemifacial myohyperplasia (HFMH) is a rare cause of facial asymmetry exclusively involving facial muscles. The underlying cause and the mechanism of disease progression are unknown. Here, we identified a somatic gain-of-function mutation of PIK3CA in five pediatric patients with HFMH. To understand the physiopathology of muscle hypertrophy in this context, we created a mouse model carrying specifically a PIK3CA mutation in skeletal muscles. PIK3CA gain-of-function mutation led to striated muscle cell hypertrophy, mitochondria dysfunction, and hypoglycemia with low circulating insulin levels. Alpelisib treatment, an approved PIK3CA inhibitor, was able to prevent and reduce muscle hypertrophy in the mouse model with correction of endocrine anomalies. Based on these findings, we treated the five HFMH patients. All patients demonstrated clinical, esthetical, and radiological improvement with proof of target engagement. In conclusion, we show that HFMH is due to somatic alteration of PIK3CA and is accessible to pharmacological intervention.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:220 |
|---|---|
| Enthalten in: |
The Journal of experimental medicine - 220(2023), 11 vom: 06. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bayard, Charles [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Class I Phosphatidylinositol 3-Kinases |
|---|
| Anmerkungen: |
Date Completed 18.09.2023 Date Revised 16.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1084/jem.20230926 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362101035 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362101035 | ||
| 003 | DE-627 | ||
| 005 | 20240316232542.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1084/jem.20230926 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1332.xml |
| 035 | |a (DE-627)NLM362101035 | ||
| 035 | |a (NLM)37712948 | ||
| 035 | |a (PII)e20230926 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bayard, Charles |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hemifacial myohyperplasia is due to somatic muscular PIK3CA gain-of-function mutations and responds to pharmacological inhibition |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.09.2023 | ||
| 500 | |a Date Revised 16.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Bayard et al. | ||
| 520 | |a Hemifacial myohyperplasia (HFMH) is a rare cause of facial asymmetry exclusively involving facial muscles. The underlying cause and the mechanism of disease progression are unknown. Here, we identified a somatic gain-of-function mutation of PIK3CA in five pediatric patients with HFMH. To understand the physiopathology of muscle hypertrophy in this context, we created a mouse model carrying specifically a PIK3CA mutation in skeletal muscles. PIK3CA gain-of-function mutation led to striated muscle cell hypertrophy, mitochondria dysfunction, and hypoglycemia with low circulating insulin levels. Alpelisib treatment, an approved PIK3CA inhibitor, was able to prevent and reduce muscle hypertrophy in the mouse model with correction of endocrine anomalies. Based on these findings, we treated the five HFMH patients. All patients demonstrated clinical, esthetical, and radiological improvement with proof of target engagement. In conclusion, we show that HFMH is due to somatic alteration of PIK3CA and is accessible to pharmacological intervention | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Class I Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 650 | 7 | |a PIK3CA protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 700 | 1 | |a Segna, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Taverne, Maxime |e verfasserin |4 aut | |
| 700 | 1 | |a Fraissenon, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Hennocq, Quentin |e verfasserin |4 aut | |
| 700 | 1 | |a Periou, Baptiste |e verfasserin |4 aut | |
| 700 | 1 | |a Zerbib, Lola |e verfasserin |4 aut | |
| 700 | 1 | |a Ladraa, Sophia |e verfasserin |4 aut | |
| 700 | 1 | |a Chapelle, Célia |e verfasserin |4 aut | |
| 700 | 1 | |a Hoguin, Clément |e verfasserin |4 aut | |
| 700 | 1 | |a Kaltenbach, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Villarese, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Asnafi, Vahid |e verfasserin |4 aut | |
| 700 | 1 | |a Broissand, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Nemazanyy, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Autret, Gwennhael |e verfasserin |4 aut | |
| 700 | 1 | |a Goudin, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Legendre, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Authier, François-Jérôme |e verfasserin |4 aut | |
| 700 | 1 | |a Viel, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Tavitian, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Gitiaux, Cyril |e verfasserin |4 aut | |
| 700 | 1 | |a Fraitag, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Duong, Jean-Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Delcros, Clarisse |e verfasserin |4 aut | |
| 700 | 1 | |a Sergent, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Picard, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Dussiot, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Guibaud, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Khonsari, Roman |e verfasserin |4 aut | |
| 700 | 1 | |a Canaud, Guillaume |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of experimental medicine |d 1896 |g 220(2023), 11 vom: 06. Nov. |w (DE-627)NLM000005967 |x 1540-9538 |7 nnns |
| 773 | 1 | 8 | |g volume:220 |g year:2023 |g number:11 |g day:06 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1084/jem.20230926 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 220 |j 2023 |e 11 |b 06 |c 11 | ||